【摘要】 目的探讨希罗达为主的联合化疗方案治疗复发转移性乳腺癌的疗效及毒副反应。方法42例复发转移性乳腺癌患者中,21例予以希罗达联合诺维本治疗;14例予以希罗达联合多西紫杉醇治疗;7例予以希罗达联合吉西他滨治疗。21 d为1周期,2周期后评价疗效。结果41例可评价患者中,治疗后完全缓解(CR)8例,部分缓解(PR)16例,稳定(SD)9例,进展(PD)8例,有效率为58.54%。中位疾病进展时间为7.4个月,中位生存时间15.3个月。主要毒副反应为白细胞减少,其中Ⅲ~Ⅳ度占41.46%。结论希罗达为主的联合化疗方案治疗复发转移性乳腺癌疗效确切,毒性反应可耐受。更多还原

【Abstract】 Objective To investigate the efficacy and toxicity of xeloda-based combination chemotherapy to the patients with recurrent metastatic breast cancer.Methods Of the forty-two patients with recurrent metastatic breast cancer,twenty-one received the regimen of xeloda plus vinorebine,fourteen received the regimen of xeloda plus docetaxed,seven received the regimen of xeloda plus gemicitabine.The regimen was repeated every 21 days and the clinical response was assessed after two cycles.Results There were 8 CR,16 PR,9 SD,and 8 PD among 41 assessable patients,the response rate was 58.54%(24/41).The median time to progression(TTP) was 7.4 months,and median survival time(MST) was 15.3 months.The major toxicity was leukopenia(41.46% in grade Ⅲ-Ⅳ).Conclusion Better clinical effects had been achieved in the therapy of recurrent metastatic breast cancer by xeloda-based combination chemotherapy and toxicities are tolerable.更多还原